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Background: There are few available therapeutic options to promote recovery among
patients with chronic disorders of consciousness (DOC). Among pharmacological
treatments, apomorphine, a dopamine agonist, has exhibited promising behavioral
effects and safety of use in small-sample pilot studies. The true efficacy of the drug and
its neural mechanism are still unclear. Apomorphine may act through a modulation of the
anterior forebrain mesocircuit, but neuroimaging and neurophysiological investigations
to test this hypothesis are scarce. This clinical trial aims to (1) assess the treatment
effect of subcutaneous apomorphine infusions in patients with DOC, (2) better identify
the phenotype of responders to treatment, (3) evaluate tolerance and side effects in
this population, and (4) examine the neural networks underlying its modulating action
on consciousness.
Methods/Design: This study is a prospective double-blind randomized parallel
placebo-controlled trial. Forty-eight patients diagnosed with DOC will be randomized to
receive a 30-day regimen of either apomorphine hydrochloride or placebo subcutaneous
infusions. Patients will be monitored at baseline 30 days before initiation of therapy, during
treatment and for 30 days after treatment washout, using standardized behavioral scales
(Coma Recovery Scale-Revised, Nociception Coma Scale-Revised), neurophysiological
measures (electroencephalography, body temperature, actigraphy) and brain imaging
(magnetic resonance imaging, positron emission tomography). Behavioral follow-up will
be performed up to 2 years using structured phone interviews. Analyses will look for
changes in behavioral status, circadian rhythmicity, brain metabolism, and functional
connectivity at the individual level (comparing before and after treatment) and at the
group level (comparing apomorphine and placebo arms, and comparing responder and
non-responder groups).
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Discussion: This study investigates the use of apomorphine for the recovery of
consciousness in the first randomized placebo-controlled double-blind trial using
multimodal assessments. The results will contribute to define the role of dopamine
agonists for the treatment of these challenging conditions and identify the neural
correlates to their action. Results will bring objective evidence to further assess the
modulation of the anterior forebrain mesocircuit by pharmacological agents, which may
open new therapeutic perspectives.
Clinical Trial Registration: EudraCT n◦2018-003144-23; Clinicaltrials.gov
n◦NCT03623828 (https://clinicaltrials.gov/ct2/show/NCT03623828).
Keywords: disorders of consciousness, unresponsive wakefulness syndrome, minimally conscious state,
apomorphine, dopamine, mesocircuit, clinical trial, protocol
INTRODUCTION
Following severe brain injury, patients who emerge from coma
may develop disorders of consciousness (DOC) such as the
unresponsive wakefulness syndrome (UWS) or the minimally
conscious state (MCS). UWS patients only present reflex
behaviors (1) whereas MCS patients demonstrate unequivocal
but inconsistent evidence of awareness through a wide variety
of behavioral responses that can be demonstrated at the bedside.
However, they are not able to functionally communicate or use
objects (2).
Treating the Severely Brain-Injured
There are currently no international guidelines to treat patients
with chronic DOC and available therapies have demonstrated
limited efficacy so far. Moreover, most of the available
information to date arises from uncontrolled studies. Several
non-pharmacological and pharmacological treatments have,
however, shown positive preliminary results. Transcranial direct
current stimulation (tDCS) on the dorsolateral prefrontal cortex
(i.e., a non-invasive neurostimulation technique) could induce
short-term behavioral improvements in 50% of patients in
a chronic MCS, without similar effects observed in patients
with UWS (3). When applied repeatedly for 5 consecutive
days, tDCS elicited effects up to a week after the end of
stimulations in 56% of MCS patients (4). Recent results suggest
the applicability of this technique in a home-based setting
(5), but further research is needed to confirm long-term
efficacy and tolerance (6). Moderate behavioral improvements
have also been observed after deep brain stimulation on the
central thalamus, but only a limited fraction of patients were
eligible for this intervention which is associated with significant
side effects related to invasive brain surgery (7–9). Among
pharmacological treatments, zolpidem (a non-benzodiazepine
hypnotic that potentiates GABAA receptors) could paradoxically
improve behavioral responsiveness in severely brain-injured
patients but effects were short-lasting and reported in only a
small minority of patients with DOC (10, 11). Because of the
role of dopamine as a general stimulatory neurotransmitter
(12) and in maintaining wakefulness in circadian rhythms (13),
several dopaminergic agents have been used in an attempt to
stimulate UWS and MCS patients (14, 15), namely levodopa,
bromocriptine, amantadine, and apomorphine (16).
Levodopa is a dopaminergic agent commonly used for
the treatment of Parkinson’s disease. Previous studies have
shown positive behavioral effects in UWS patients after its
administration (17, 18). The effects observed within 10 days
of treatment included the recovery of command-following and
reciprocal interaction. Bromocriptine is another dopaminergic
agonist acting on postsynaptic dopamine D2 receptors, also used
primarily as anti-Parkinsonian therapy. It has been associated
with a higher rate of patients recovering from a post-traumatic
UWS in a retrospective study (19). However, in a 6-week double-
blind, placebo-controlled, crossover study, bromocriptine did not
improve attentional skills in 12 conscious patients with moderate
to severe traumatic brain injury (20). Last, amantadine is used
as an antiviral and as an anti-Parkinsonian agent, acting as
a weak antagonist of the NMDA-type glutamate receptor as
well as increasing dopamine release and blocking its reuptake.
One placebo-controlled study has shown its efficacy to increase
recovery rate in UWS andMCS patients suffering from traumatic
brain injury, although no difference with the placebo group was
observed 2 weeks after washout (21). Based on these results,
amantadine is currently the only drug recommended in the
recently published American practice guidelines for DOC for the
treatment of UWS and MCS patients between 4 and 16 weeks
following brain injury (22).
Apomorphine—A Promising Agent to
Improve Recovery
Two small-sample uncontrolled studies have shown that
apomorphine, a nonselective dopamine agonist with a high
affinity for D2 receptors, may dramatically improve the outcome
of patients with UWS and MCS (23, 24). While other agents
increase the availability of natural dopamine by modulating
synaptic reuptake rates, apomorphine exerts a direct action
on dopamine receptors, which entails the activation of its
target neurons regardless of axonal damages (25, 26). Its fast
action, high bioavailability and subcutaneous administration
allow accurate and steady drug blood levels (27). It is marketed
with an indication for advanced Parkinson disease refractory
to treatment, and has a well-documented safety profile, causing
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mainly minor and manageable side effects such as local skin
nodules, nausea, and hypotension (28–30). All eight patients
with traumatic brain injury treated with apomorphine showed
significant behavioral improvements within 1 to 62 days of
treatment (24). These patients had been previously treated
with other dopaminergic stimulants without response, whereas
apomorphine elicited significant effects. However, the lack
of a control group did not allow to fully disentangle the
responses due to apomorphine treatment of these patients
from possible spontaneous recovery. In addition, no study has
investigated the neural mechanisms underlying the action of
apomorphine in patients with DOC, although some hypotheses
have been formulated.
The Mesocircuit Model—A Framework for
the Role of Dopamine
The mesocircuit model (31) could help us understand the
behavioral response to dopaminergic agents in severely brain-
injured patients. This model explains the vulnerability of the
anterior forebrain following multi-focal brain injuries that
produce widespread deafferentation or neuronal cell loss.
Decreased projections from the central thalamus and the frontal
cortex cause an insufficient afferent drive on the dopaminergic
medium spiny neurons of the striatum, which fail to actively
inhibit the globus pallidus interna. The globus pallidus interna
inhibits central thalamic neurons which in turn fail to sustain
their activating projections on cortical areas (32). Impairment
of these loops mainly relying on dopamine could lead to a
broad synaptic activity decrease in areas responsible for the
generation of consciousness (33). Abnormalities of dopamine
neurotransmission, such as reductions in dopamine transporter
and expression of D2 receptor, have been reported in patients
after closed-head trauma, which supports the postulated central
role of dopamine in severe brain injury (34–36).
Treatment by exogenous dopaminergic agonists would
hypothetically increase the firing rate of medium spiny neurons
in the striatum and facilitate projections inhibiting the globus
pallidus interna, restoring the loops between the cortex, the
striatum, the globus pallidus interna and central thalamic nuclei
[Figure 1; (37)]. In particular, the high density of D2-type
inhibitory medium spiny neurons in the striatum suggests
that agents with a higher affinity for this receptor, such as
apomorphine, may be suitable therapeutic candidates (34). The
postulated resulting central thalamic modulation would be in
line with the previously described restoration of thalamo-cortical
connectivity following spontaneous recovery from UWS (38),
as well as clinical improvements obtained with deep brain
stimulation of the central thalamus in MCS patients (9).
In the light of the above, we therefore propose to investigate
the effects of apomorphine in patients with DOC in a multimodal
placebo-controlled clinical trial including neuroimaging and
neurophysiology techniques.
Study Objectives
This research aims to (1) evaluate the effect of apomorphine
treatment for the recovery of consciousness among patients
with UWS and MCS in a placebo-controlled setting to better
FIGURE 1 | The mesocircuit hypothesis. (A) Normal wakeful condition.
Dopamine neurons in the striatum inhibit the pallidum, which prevents it from
inhibiting the thalamus. Thalamic projections activate cortical networks and get
positive feedback in return. Excitatory inputs from both the cortex and the
thalamus activate the striatum to maintain the loop. (B) Brain injury. Withdrawal
of thalamostriatal and corticostriatal projections following widespread neuronal
deafferentation leads to reduced activity of the striatum, resulting in an
inhibition of thalamic activity and decreased cortical activation. (C) Postulated
action of apomorphine (APO) on brain injury. The facilitating action of
apomorphine on striatal dopamine neurons could substitute for the missing
inputs and restore the inhibitory striatopallidal projections, thus freeing the
thalamus and its output toward the cortex.
characterize the nature, size and duration of this effect, (2)
better define the phenotype of potential good candidates to
apomorphine treatment and identify a set of biomarkers that
correlate with responsiveness (or non-responsiveness) to the
therapy, (3) evaluate the tolerance and the occurrence of side
effects of daily subcutaneous apomorphine infusions in this
vulnerable population, and (4) investigate the neural mechanisms
underlying the action of apomorphine treatment in severe brain
injury using neurophysiological and neuroimaging assessments
to detect brain activity changes, with the mesocircuit model as
theoretical framework. Not only will these results help to define
clearer guidelines in the treatment of patients with DOC, but they
will also allow a better understanding of how dopamine networks
are involved in consciousness and its impairments.
Study Hypotheses
Ourmain hypothesis is that apomorphine treatment will increase
responsiveness and induce behavioral changes in a significant
fraction of the patient population. We expect that these changes
will in some cases improve the patients’ diagnosis, according to
the Coma Recovery Scale-Revised (CRS-R) guidelines (39).
We surmise that the recovery of physiological circadian
sleep-wake cycles, measured by actigraphy, core body
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temperature monitoring and sleep architecture assessed by
night electroencephalography (EEG), may be correlated with
behavioral responsiveness to the therapy. Total movements as
measured by actigraphymay also increase in responding patients.
Based on the mesocircuit model, we hypothesize that
responders to the treatment will show an increase of axonal
projections from the striatum to the globus pallidus interna,
restoring central thalamic activity, and resulting in higher
integration of neuronal activity across the cortex. We postulate
that these changes will translate into modifications of brain
metabolism and functional connectivity. We expect an
improvement in brain metabolism measured by fludeoxyglucose
positron emission tomography (FDG-PET), with significant
increases of whole brain glucose standardized uptake value
after treatment, in particular in the striatum, thalamus
and frontoparietal areas. We also predict a modulation of
functional connectivity by apomorphine treatment measured
by resting-state functional magnetic resonance imaging (fMRI)
seed-based analyses as well as increased resting-state EEG
dynamic connectivity and spectral power metrics (e.g., mean
alpha spectral connectivity, participation coefficient variance,
delta modularity).
METHODS
Study Design
This is a prospective double-blind randomized parallel placebo-
controlled trial. The trial will be preceded by an open-label pilot
phase on six patients with the same study design except for the
absence of a control group, to assess feasibility.
Population and Recruitment
We will include 48 patients with DOC following severe acquired
brain injury. All participants will be inpatients undergoing
neurological rehabilitation in the post-coma unit. Patients will
be assessed by the referring neurologist at the time of their
admission and eligibility for the study will be determined.
An accredited examiner will determine the diagnosis using
standardized CRS-R criteria.
The inclusion and exclusion criteria are as follows:
Inclusion criteria:
– 18–55 years old.
– Clinically stable, independent of medical ventilators
for respiration.
– Diagnosed as in an UWS or MCS according to the
international criteria and based on at least 2 consistent CRS-R
in the last 14 days (one CRS-R in the last 7 days).
– More than 4 weeks from onset of the injury.
– Informed consent from legal representative of the patient (and
from the patients in the event they recover legal capacity).
Exclusion criteria:
– More than 6 months from onset of the injury.
– Use of dopamine agonists or antagonists (e.g., amantadine,
bromocriptine, levodopa, pramipexole, ropinirole,
amphetamine, bupropion, methylphenidate/risperidone,
haloperidol, chlorpromazine, flupentixol, clozapine,
olanzapine, quetiapine) during the last 2 weeks or 4 half-lives
of the drug.
– Use of neurological medications other than anticonvulsant or
anti-spasticity drugs during the last 2 weeks or 4 half-lives of
the drug.
– Use of drugs with known significant prolongation of the
QT interval (e.g., class 1 antiarrythmics, sotalol, macrolides,
quinolones, antipsychotic drugs, tricyclic antidepressants,
methadone, chloroquine, quinine) during the last 2 weeks or
4 half-lives of the drug.
– A corrected QT interval over 480ms (calculated using Bazett’s
formula on a standard 12-lead ECG, recorded in the last
14 days) or other risk factors for arrhythmia (congestive
cardiac failure, severe hepatic impairment, or significant
electrolyte disturbance).
– A history of previous neurological chronic disorder other than
related to their acquired brain injury.
– Contraindication to MRI, EEG, or PET (e.g., electronic
implanted devices, external ventricular drain).
– Use of nitrates or other vasodilators, central nervous system
acting agents such as barbiturates, morphine, and related
drugs (relative exclusion criterion).
Procedure
Twenty-four of the included patients will be randomly assigned
to the apomorphine group and twenty-four to the placebo group.
Random allocation will be performed using a computerized
random number generator to achieve blocked randomization.
The assignment sequence will be generated and known only by
two main investigators not involved in patient assessment, who
will communicate the assigned intervention to the referent site
pharmacist for each patient after enrollment. The pharmacist will
then prepare the product and deliver it to the care providers in a
neutral packaging. The assignment to interventions as well as the
size of the blocks will be concealed to the patient, their relatives,
the care providers, and all investigators performing patient
recruitment, bedside assessments and data analysis. Concealment
will be maintained after assignment during baseline assessment,
treatment, and inpatient follow-up, following a double-blind
design. Investigators performing data analyses will remain blind
for the whole duration of the study. Figure 2 illustrates the
clinical protocol procedure.
Baseline Assessment
The initial 3 weeks (day 1 to day 21) after inclusion in the
study (“baseline”), patients will be assessed once a week using
the CRS-R and the Nociception Coma Scale-Revised [NCS-R,
(40)] in order to have a reliable diagnosis and a measure of
pain levels. One week before starting the treatment (day 22 to
day 28), patients will undergo a multimodal assessment with
CRS-R, NCS-R, MRI, FDG-PET and high density EEG during
resting state and during auditory paradigms. Actigraphy and
body temperature data will be recorded continuously from day
1 up to day 90.
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FIGURE 2 | Timeline of the study protocol. Blue segments: inpatient phases; Orange segments: multimodal assessments; Green segment: outpatient remote
follow-up; dashed line: optional treatment extension; CRS-R, Coma Recovery Scale-Revised; NCS-R, Nociception Coma Scale-Revised; EEG,
electroencephalography; PET, positron emission tomography; MRI, magnetic resonance imaging; T◦, body core temperature; GOS-E, Glasgow Outcome
Scale-Extended; Red crosses, 24 h EEG.
Treatment Phase
From day 31 to day 60, patients will be administrated
apomorphine or placebo. Based on the dosing schedule used
in previous studies (24), apomorphine will be administered
subcutaneously 12 h per day during daytime (∼09:00 am−09:00
pm) with an initial increase of doses: 1 mg/hour on day 31,
1.5 mg/hour on day 32, 2 mg/hour on days 33 and 34, up
to 4 mg/hour from day 35 up to day 42 if no substantial
adverse effect is noted. On day 43, depending on the patient’s
tolerance, clinical response and expected benefit, the referent
physician will be given the choice to increase the infusion rate
to 6 mg/hour or to keep it at 4 mg/hour until day 60. If the
referent physician considers necessary at any time during the
treatment (e.g., in case of significant side effects), the infusion
will be decreased to the prior rate or stopped. A subsequent
increase of dose will only be considered after clinical stability
for a minimum of 7 days. Placebo will consist of isotonic
saline infusions delivered via subcutaneous apomorphine pump.
Placebo and apomorphine will be conditioned with similar
packaging, labeling and product aspect.
Two days prior to the initiation of treatment, 20mg t.i.d
of domperidone will be administered to all patients to reduce
possible side effects such as nausea and vomiting. Antiemetics
will be maintained for a minimum of 7 days before tapering off. It
can also be continued beyond this point at equal or lower dosage
if the referent physician deems necessary.With these precautions,
side effects (nausea, vomiting, and hypotension) related to
apomorphine administration will be significantly reduced (28).
A standard 12-lead ECG will be performed before the initiation
of treatment to rule out long QT interval, as both apomorphine
and domperidone may prolong QT interval and increase the risk
for arrhythmias (41, 42).
During treatment phase, behavioral assessments (CRS-R and
NCS-R) and resting-state EEG will be performed weekly. Sleep
EEG will be recorded once just before treatment initiation and
once after treatment termination.
Follow-Up
Immediately after the cessation of the treatment (day 61 or
earlier if treatment terminated), all patients will undergo another
multimodal assessment (see Baseline Assessment). Between day
61 and day 90, patients will be assessed weekly with the CRS-R,
NCS-R, and resting-state EEG (Figure 2).
The presence of adverse effects will be recorded weekly from
the initiation of treatment (day 31) until the end of the washout
follow-up (day 90) using an Adverse Events Questionnaire form
(Supplementary Data 1).
If, after day 90, the patient’s clinical state deteriorates after
treatment withdrawal to the point of a negative CRS-R diagnosis
change, the referent physician will be given the option to resume
apomorphine treatment using the last prescribed dose after
progressive escalation. The duration of the extension will be
determined by the referent physician based on clinical judgment.
Remote follow-up evaluations by structured phone interviews
will also be carried out at 6 months, 1 and 2 years post-
evaluation using the Glasgow Outcome Scale-Extended (43),
a phone-adapted version of the CRS-R and the Adverse
Events Questionnaire.
Instruments
We will employ the following clinical, neurophysiological, and
neuroimaging techniques:
Apomorphine or Placebo Treatment
Patients will be randomized at inclusion to receive either
apomorphine hydrochloride at a 5 mg/mL concentration, as
available in pre-filled syringes, or normal saline placebo (sodium
chloride 9 mg/mL) matched for fluid volume and aspect.
Apomorphine will be administered by subcutaneous infusions
using a Crono APO-go III pump (Britannia Pharmaceuticals,
Reading, UK). The tank of the pump will be filled by the study
pharmacist with either apomorphine or placebo according to
the patient’s assigned intervention, and a clinical trial label will
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be displayed on the pump. Subcutaneous infusions lines will be
placed using a 20- to 30-gauge metal butterfly needle and the
infusion site will be chosen at the discretion of the clinical staff,
according to themanufacturer’s guidelines (e.g., below umbilicus,
upper outer thighs, shoulder). The infusion site will be changed
at the beginning of each day using a new sterile needle, or more
often if local adverse effects are noted during the infusion.
The treatment will start with a titration phase designed to
determine the optimal tolerated dose for each patient. The
maintenance phase will then follow, for a total of 30 days of
treatment. Infusion will take place 12 h a day during daytime
(∼09:00 am−09:00 pm) to avoid perturbing sleep-wake cycles.
Behavioral Assessments
The CRS-R is the gold standard behavioral scale for diagnosis
of consciousness (44). This scale comprises 23 items, separated
into six subscales, assessing the visual, motor, auditory, and oro-
motor/verbal functions as well as communication and arousal.
The diagnosis relies on the presence or absence of specific items
for each diagnostic entity, rather than the total calculated score
(39). A modified score has been developed to detect conscious
awareness with a higher sensitivity and specificity than the total
score, using a single metric (45).We will use the validated French
version of the CRS-R for French-speaking patients (46).
The NCS-R was created in order to detect pain in DOC
patients. This scale assesses reactions to noxious stimulation and
scores for motor, verbal, and facial responses. Its total score
ranges from 0 (no pain) to 9 (maximal pain) (40).
The Glasgow Outcome Scale-Extended is used to classify
global outcomes in traumatic brain injury survivors within 8
categories: dead, vegetative state, lower severe disability, upper
severe disability, lower moderate disability, upper moderate
disability, lower good recovery and upper good recovery (43). A
structured phone interview version of the scale will be used to
allow remote follow-up of recovery.
The phone-adapted version of the CRS-R is a tool developed
to assess the most significant items of the CRS-R (i.e., key criteria
for the diagnosis of MCS and emergence of MCS) through a
structured phone interview based on the observations of relatives
and caregivers during the last 2 weeks and provides a diagnosis.
The Adverse Events Questionnaire (Supplementary Data 1)
is designed to probe the most frequent adverse events
associated with the administration of apomorphine and
allows the referent physician to report the nature, the
severity and the probable causality of new adverse events.
It was created for this trial using available information
on the most frequent adverse events associated with
apomorphine (28, 42).
Circadian Rhythm
Circadian rhythmicity describes the cyclic variations of body
parameters over a 24 h period. This process is regulated by
light intensity changes which triggers melatonin release during
the night and its inhibition during the day. Among patients
with DOC, it is still unclear how the circadian rhythm is
altered and more importantly how it affects their sleep and
cognition (47, 48). Variations in spontaneous movements, body
core temperature, and EEG activity can be used in order to
monitor biomarkers reflecting the circadian rhythm throughout
day and night. From the beginning of baseline assessment (day
0) to the end of washout follow-up (day 90), a wrist actimeter
(MotionWatch 8, CamNtech Ltd., Cambridge, UK) will measure
the patient’s spontaneous movements continuously and non-
invasive temperature sensors (iButtons, Maxim Integrated, San
Jose, CA, USA) will record core body temperature at 4 points
of the body (subclavicular and interior malleola), as well as
room temperature (49). Twenty-four-hour EEG recordings (23
channels, Grass Comet Plus, Natus Medical Inc, Pleasanton, CA,
USA) will be performed before and after apomorphine treatment,
in order to analyze sleep architecture changes (50).
EEG
EEG is the recording of electrical brain activity along the scalp.
EEG measures voltage fluctuations resulting from ionic current
flows within ensembles of neurons. In clinical context, event-
related potentials (ERPs) involve averaging the EEG activity time-
locked to the presentation of a stimulus. The presence of specific
auditory ERPs such as themismatch negativity of the P300 is well-
known to reflect the ability to cognitively process sounds (51).
The recording of these effects has been used as a noninvasive
tool to assess levels of consciousness and predict outcomes of
DOC patients (52). EEG activity will be recorded during resting-
state and during a “local-global” oddball auditory paradigm,
which allows an orthogonal manipulation of automatic and
conscious responses to irregularity (53). Multivariate classifiers
using machine learning were recently developed to stratify
patients with DOC using an array of individual EEG metrics
reflecting ERPs, spectral measures, information, and connectivity
(54, 55). In addition, the resting-state data can be used to evaluate
spectral connectivity using graph-theoretic metrics, which have
proven to correlate with behavioral recovery of patients (56).
We will use a high-density EEG device (256 channels,
Electrical Geodesics Inc, Eugene, OR, USA) and a conventional
EEG device (23 channels, Grass Comet Plus, Natus Medical Inc,
Pleasanton, CA, USA).
FDG-PET
FDG-PET is a technique where radioactively labeled isotopes
are incorporated in certain chemical substances (tracers) and
infused in the blood. By simultaneous external detection of
the radioactively-emitted particles, the uptake of the tracer can
be calculated across the brain. With the FDG tracer, glucose
transport and metabolism can be measured. The patient will lie
still in a darkened room for 15min before tracer injection. After
the injection, high-density EEG recordings will be performed
during the cerebral uptake of the tracer. PET scanning will be
performed 30min after the tracer injection. If the patient is
agitated before the scanning, sedation will be initiated using the
lowest possible doses in order to reduce head motion and obtain
better-quality images (PET images are sensitive to head motion).
The sedation will be administered after the tracer uptake period
such that measured brain metabolism is not affected. Sedation
will last only the time of the exam and an anesthesiologist will
be present during the whole exam. FDG-PET scanning will be
Frontiers in Neurology | www.frontiersin.org 6 March 2019 | Volume 10 | Article 248
Sanz et al. Apomorphine Randomized Controlled Trial Protocol
performed using a Gemini TF PET/CT scanner (Koninklijke
Philips N.V., Amsterdam, the Netherlands). PET acquisition
procedures and image processing will be similar to previously
described methods (57, 58).
Magnetic Resonance Imaging (MRI)
Structural MRI enables visualization of internal structures of
the brain. Structural sequences (T1, T2-FLAIR and diffusion
tensor imaging sequences) provide information on the anatomy
of the brain and a voxel-based morphometry approach will
allow to measure the loss of gray matter volume compared to
healthy controls (59). Functional MRI will also be acquired with
sequences that can evaluate the resting-state activity and the
functional connectivity of different brain networks (e.g., default
mode, auditory, visual, salience, motor networks) (60, 61). MRI
images are sensitive to head motion, therefore if the patient is
restless before the scanning, sedation will be administered by an
anesthesiologist. MRI will be performed with a 3TMAGNETOM
Vida MRI scanner (Siemens, Munich, Germany).
Electronic Data Collection and
Management
All information collected during this study will be kept
confidential. The data will be pseudo-anonymized and listed
under an ID-code only accessible to researchers at the GIGA
Consciousness, and protected by a firewall. Participants will have
a right to inspect, correct and request the deletion of their
personal data at any time for 20 years after the inclusion in
the trial. Data management will comply with the General Data
Protection Regulation (EU 2016/679) and a specific information
sheet will inform patients or their legal representative of the
nature of collected data and their rights regarding these data.
Statistical Analyses
Analyses will focus on the detection of changes induced by
apomorphine treatment at the individual level (comparing data
before and after treatment) and at the group level (comparing
the placebo arm to the treatment arm). Along with the nature
of the assigned intervention, age, etiology, time since injury
and diagnosis will be included as additional independent
variables in the regression analyses as they have proved to
influence the prognosis of patients with DOC (62). CRS-R
diagnosis will be used as primary outcome measure. Secondary
outcomes will include metrics on different levels: (1) behavioral
assessments (CRS-R total score and modified score, NCS-R,
GOS-E, phone-adapted CRS-R), (2) brain metabolism (PET
scan), (3) functional connectivity (resting-state fMRI, resting-
state high-density EEG), (4) circadian rhythm (actigraphy, core
body temperature, sleep architecture), and (5) drug safety
(Adverse Effects Questionnaire).
Statistical analysis of PET and fMRI data will be performed
with statistical parametric mapping (SPM12, https://www.fil.
ion.ucl.ac.uk/spm/) and CONN functional connectivity toolbox
(http://www.nitrc.org/projects/conn/) (60, 63). Quantification of
PET signal will use methods based on standardized uptake
values of FDG (64). MRI functional connectivity will be probed
with the seed-voxel approach, which determines temporal
correlations and anti-correlations between regions of interest
and the time course from all other brain voxels (65, 66).
EEG data analysis will use EEGLAB (https://sccn.ucsd.edu/
eeglab/) and FieldTrip (http://www.fieldtriptoolbox.org/) for
the estimation of spectral power within fixed bands, and
dynamic connectivity will be estimated using median spectral
connectivity and graph-theoretic topology metrics such as
clustering coefficient, path length, modularity and participation
coefficient (56). “Local-global” EEG recordings will be analyzed
with a multivariate classifier based on machine learning using
an array of individual EEG metrics (54). Results will be
corrected for multiple comparisons and considered statistically
significant when p < 0.05. Significant results will be examined in
terms of relevance to the treatment administered to determine
whether they carry clinical importance in the context of this
clinical trial.
Power Study
The sample size for this clinical trial was determined using a
study power calculation (G∗Power, UCLA, CA, USA) for a two-
sampled t-test based on the best available data regarding the
effect size of apomorphine treatment. In the largest study to
date for this indication (24), 75% of patients (6/8) reached a
status of moderate disability or good recovery one year after
treatment, while 24% of subjects attained this status at the same
time point in a roughly comparable cohort of 443 patients
with DOC following traumatic brain injury (67). To account
for the dissimilarities between these two populations and the
possible overestimation of the treatment effect in Fridman’s study
due to small sample size, a 1% type-1 and 20% type-2 error
rate threshold was set, resulting in an ideal sample size of 42
subjects. Assuming a drop-out rate of 12.5%, in line with previous
studies conducted in our department, we set the sample size to
48 patients.
Dissemination of Results
All collected data will be kept anonymously in a protected
database at the University of Liège, Belgium, in compliance with
the (EU) 2016/679 General Data Protection Regulation.
Anticipated dissemination of results includes scientific
publications in international peer-reviewed journals, with
open access on institutional repositories as required by Belgian
legislation. The publication plan forecasts one first article
after the initial open-label pilot study. After completion of the
inpatient phase of the trial, we aim to deliver one article reporting
behavioral (CRS-R, NCS-R), brain metabolism (FDG-PET), and
drug safety results, one article reporting brain connectivity
(MRI and EEG) and one article on circadian rhythm (core body
temperature and actigraphy) data. An additional article reporting
the long-term outcomes of participants after full completion of
the trial is also expected.
DISCUSSION
Patients with chronic DOC are too often neglected by healthcare
infrastructures and health insurance systems, which leads to a
frequent suboptimal medical management of their condition
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(68). This increases the risk of both misdiagnosis (69), and
failure to offer adequate and targeted treatment. Indeed, it
has been demonstrated that the few available pharmacological
therapies have limited efficacy to certain specific patient sub-
populations (70). For these reasons, it is crucial that further
research verifies the effect of available treatments within a
controlled setting, and defines more clearly the characteristics
of potential therapy responders. This protocol describes the first
randomized clinical trial on the efficacy of apomorphine for
the recovery of consciousness using multimodal assessments.
It aims to confirm preliminary results observed in small-
sample, non-controlled studies, and to better identify the
functional phenotype of responders. This study will use the
anterior forebrain mesocircuit model (31) as a framework
to understand the action of dopaminergic agents for the
restoration of consciousness. We will use neuroimaging
to test the hypothesis that apomorphine modulates these
striato-pallido-thalamo-cortical loops through a dopamine-
dependent action (23). As such, this trial will bring direct
evidence to challenge the mesocircuit model and shed new
light on the neural mechanism of dopaminergic treatment for
chronic DOC. Pinpointing neuroimaging changes induced by
apomorphine treatment will allow us to compare our results
with available evidence on the action of other pharmacological
therapies for DOC. Indeed, it has been hypothesized that
“awakening” drugs acting on diverging neurotransmitter systems
(dopamine, GABA) may in fact operate through a common
activating pattern restoring the mesocircuit functional loops
(71). This model would be supported by the identification
of neuroimaging features in responders to apomorphine
treatment similar to those described for zolpidem and
amantadine (16).
The main potential pitfall of this clinical trial is a possible
overestimation of the treatment effect size and response rate
based on available literature, due to the non-controlled nature
of previous studies. This would lead to an inaccurate estimation
of the necessary sample size, which may lead to insufficient
power. An extension of the population size is planned if
intermediate analyses reveal an effect size substantially lower than
expected. Unexpected severe adverse effects are very unlikely
given the well-documented safety profile of apomorphine and
the extensive experience of its use in Parkinson’s disease.
Safety of the participants will be maximized by the use of
the Adverse Events Questionnaire, the requirement to report
immediately any severe adverse event and the possibility
to adapt apomorphine and domperidone dosage in case of
low tolerance.
Our findings may open new paths in the development of
treatments targeting specific brain networks or receptor subtypes,
and could reshape the therapeutic landscape for this challenging
patient population in urgent need for better healthcare.
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